表紙
市場調查報告書

半乳凝素3:開發中產品分析

Galectin 3 - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 372681
出版日期 內容資訊 英文 81 Pages
訂單完成後即時交付
價格
半乳凝素3:開發中產品分析 Galectin 3 - Pipeline Review, H1 2020
出版日期: 2020年02月28日內容資訊: 英文 81 Pages
簡介

本報告提供以半乳凝素3為標的之治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

半乳凝素3 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Angion Biomedica Corp.
  • Bristol-Myers Squibb Company
  • Galectin Therapeutics, Inc.
  • GlycoMimetics, Inc.
  • MandalMed, Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2301TDB

Summary

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Galectin-3 is a protein encoded by the LGALS3 gene. It mediates with the alpha-3, beta-1 integrin the stimulation by CSPG4 of endothelial cells migration. It acts as a pre-mRNA splicing factor. It is involved in acute inflammatory responses including neutrophil activation and adhesion, chemoattraction of monocytes macrophages, opsonization of apoptotic neutrophils, and activation of mast cells.

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) pipeline Target constitutes close to 16 molecules. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 9 and 3 respectively. Report covers products from therapy areas Oncology, Cardiovascular, Gastrointestinal, Respiratory, Undisclosed, Genito Urinary System And Sex Hormones, Immunology and Ophthalmology which include indications Liver Fibrosis, Pulmonary Fibrosis, Unspecified, Breast Cancer, Idiopathic Pulmonary Fibrosis, Myocardial Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Arrhythmias, Atrial Fibrillation, Blood Cancer, Chronic Kidney Disease (Chronic Renal Failure), Congestive Heart Failure (Heart Failure), Head And Neck Cancer Squamous Cell Carcinoma, Inflammation, Keratoconjunctivitis Sicca (Dry Eye), Kidney Fibrosis, Liver Cirrhosis, Metastatic Melanoma, Metastatic Prostate Cancer, Myelofibrosis, Myocardial Infarction, Non-Small Cell Lung Cancer, Ovarian Cancer, Plaque Psoriasis (Psoriasis Vulgaris), Portal Hypertension, Prostate Cancer, Pulmonary Arterial Hypertension, Sarcomas, Skin Cancer and Venous (Vein) Thrombosis.

The latest report Galectin 3 - Pipeline Review, H1 2020, outlays comprehensive information on the Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3)
  • The report reviews Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

Introduction

  • Global Markets Direct Report Coverage
  • Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Overview
  • Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Companies Involved in Therapeutics Development
  • G3 Pharmaceuticals Inc
  • Galectin Therapeutics Inc
  • Galecto Biotech AB
  • Glycomantra Inc
  • GlycoMimetics Inc
  • Immutics Inc
  • MandalMed Inc
  • Proteris Biotech Inc
  • Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Drug Profiles
  • belapectin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GB-0139 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GB-1211 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GB-2064 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GM-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GM-200 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GMCT-04 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GMI-1757 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GRMD-03 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GRMD-04 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IMT-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Protearin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit Galectin-3 for Cardiovascular Disease, Fibrosis and Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit LGALS3 for Cardiovascular and Genito Urinary System Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TFD-100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Dormant Products
  • Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Discontinued Products
  • Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Product Development Milestones
  • Featured News & Press Releases
  • Feb 04, 2020: Galectin Therapeutics president and CEO Dr. Harold Shlevin to present at the 3rd Global NASH Congress 2020
  • Dec 09, 2019: Galectin Therapeutics phase 2 NASH cirrhosis clinical trial results on belapectin (GR-MD-02) published in gastroenterology
  • Dec 05, 2019: Galectin Therapeutics plans adaptively designed phase 3 NASH-RX clinical trial in NASH Cirrhosis
  • Nov 11, 2019: Galectin Therapeutics reaches agreement with Siemens Healthineers to collaborate on NASH and Liver Fibrosis
  • Nov 05, 2019: Additional Ad Hoc analysis of ELF data from Galectin Therapeutics NASH-CX phase 2 clinical trial to be highlighted in poster presentation at the 2019 AASLD Liver Meeting
  • Sep 17, 2019: Galectin Therapeutics and Providence Cancer Institute receive patent on the use of Belapectin (GR-MD-02) in Cancer Immunotherapy
  • Aug 05, 2019: Galectin Therapeutics submits phase 3 NASH-RX protocol in Nash Cirrhosis to FDA
  • Mar 22, 2019: Providence Cancer Institute to Present Findings on GR-MD-02 at the 2019 Keystone Symposia on Molecular and Cellular Biology
  • Dec 04, 2018: GlycoMimetics presents poster at 60th ASH Annual Meeting highlighting preclinical data on GMI-1757
  • Nov 05, 2018: Data collected by Exalenz Bioscience in Galectin Therapeutics phase 2 NASH-CX trial of GR-MD-02 to be presented at AASLD Annual Meeting
  • Sep 20, 2018: Galectin Therapeutics announces positive preliminary results from phase 1b clinical trial of GR-MD-02 and KEYTRUDA in advanced melanoma and expansion of the Trial
  • Jul 18, 2018: GlycoMantra received SBIR Phase 1 grant from the NCI (NIH)
  • Jun 27, 2018: Galectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis
  • Jun 12, 2018: Galectin Therapeutics Announces New CEO
  • Jun 04, 2018: Galectin Therapeutics Announces Richard E. Uihlein Elected Chairman of the Board
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indications, H1 2020
  • Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by G3 Pharmaceuticals Inc, H1 2020
  • Pipeline by Galectin Therapeutics Inc, H1 2020
  • Pipeline by Galecto Biotech AB, H1 2020
  • Pipeline by Glycomantra Inc, H1 2020
  • Pipeline by GlycoMimetics Inc, H1 2020
  • Pipeline by Immutics Inc, H1 2020
  • Pipeline by MandalMed Inc, H1 2020
  • Pipeline by Proteris Biotech Inc, H1 2020
  • Dormant Products, H1 2020
  • Dormant Products, H1 2020 (Contd..1), H1 2020
  • Dormant Products, H1 2020 (Contd..2), H1 2020
  • Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020